G1 Therapeutics Inc $ 18.3 4 (27.95%)
Volume:
2,519,804
Avg Vol (1m):
969,036
Market Cap $:
690.15 Mil
Enterprise Value $:
479.61 Mil
P/E (TTM):
0.00
P/B:
3.49
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 8.57 | ||
| Equity-to-Asset | 0.77 | ||
| Debt-to-Equity | 0.14 | ||
| Debt-to-EBITDA | -0.24 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 2.63 | ||
| WACC vs ROIC | |||
Profitability Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -379.07 | ||
| Net Margin % | -380.49 | ||
| ROE % | -46.63 | ||
| ROA % | -39.9 | ||
| ROC (Joel Greenblatt) % | -922.15 | ||
| 3-Year EBITDA Growth Rate | -32.2 | ||
| 3-Year EPS without NRI Growth Rate | -26.1 |
GTHX
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 3.49 | ||
| PS Ratio | 23.98 | ||
| EV-to-EBIT | -4.2 | ||
| EV-to-EBITDA | -4.22 | ||
| EV-to-Revenue | 16.7 | ||
| Current Ratio | 7.45 | ||
| Quick Ratio | 7.45 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.2 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 3.5 | ||
| Earnings Yield (Greenblatt) % | -23.94 |